MDM2 and neoplasm: Studies have shown that ubiquitinase/deubiquitinase can be involved in cancer therapy as a target, and most studies have focused on IAP and MDM2 inhibitors, for example, the IAP inhibitor birinapant has been shown to be well tolerated in clinical trials with stable anti-tumor activity in some patients with solid tumors.162